Moderate ResearchLongevity

Vesilute

ED Dipeptide | Bladder & Urinary Tract Bioregulator

Half-life

Not established

Chain length

2 amino acids

Reference frequency

Daily for 10-20 consecutive days (Khavinson bioregulator cycle)

Research overview

DoseGear research brief

Vesilute is a Khavinson bioregulator dipeptide consisting of glutamic acid and aspartic acid (ED), developed at the St. Petersburg Institute of Bioregulation and Gerontology. It is specifically designed to support bladder and urinary tract function, with research indicating potential benefits for prostate health in men. Vesilute may help regulate smooth muscle function, enhance tissue blood flow, and support cellular regeneration in urogenital tissues. It is distinct from Vesugen (KED tripeptide), which targets vascular endothelium.

Mechanism of action

Vesilute acts on the smooth muscle cells and vascular endothelium of the urogenital system. It is proposed to: (1) regulate smooth muscle contraction and relaxation in the bladder wall, (2) enhance microcirculation and blood flow in pelvic tissues including prostate, (3) support cellular regeneration and tissue repair in the urinary tract, (4) reduce hyperemia and inflammation-related dysfunction, and (5) modulate gene expression related to urogenital tissue homeostasis through bioregulation pathways characteristic of Khavinson peptides.

Compound background

Development & research timeline

Study windows describe what researchers measured, not when an individual should expect a result.

Origin & development

Short peptide associated with Khavinson bladder-tissue bioregulator research.

What it is researched for

Experimental urinary-bladder tissue regulation through proposed gene-expression and tissue-regulatory effects.

Research observation window

Not reported in the reviewed compound-specific evidence.

Reference data

Lyophilized vial injectable protocols

Not personalized dosing instructions

Only injectable vial references are shown. Nasal, topical, and unsupported non-vial schedules are excluded.

Research context	Amount	Frequency	Route
Standard protocol	10-20 mg	Daily for 10-20 days	SubQ or IM
Maintenance	20 mg	2-3 cycles yearly	SubQ or IM

Reference cycle

10-20 day cycle

Reference storage

Lyophilized powder: room temperature or 2-8°C; Reconstituted: 2-8°C refrigerated, use within 4 weeks

Safety context

Reported side effects

Generally well-tolerated
Injection site reactions (mild, if injectable)
Minimal reported side effects

Contraindications & cautions

Known hypersensitivity to peptide components
Active urinary tract infection (treat first)
Pregnancy or breastfeeding
Prostate cancer (consult physician)

Scientific references

01
Khavinson Bioregulator Peptides: Organ-Specific Effects
Scientific citationKhavinson Bioregulator Peptides: Organ-Specific Effects. .
02
Short Peptides and Urogenital Function
Scientific citationShort Peptides and Urogenital Function. .
03
Bioregulators in Anti-Aging Medicine
Scientific citationBioregulators in Anti-Aging Medicine. .

This DoseGear profile combines published scientific literature with lyophilized-vial protocol references. Citations are provided for independent review.

Related research profiles

Longevity